https://pmc.ncbi.nlm.nih.gov/articles/PMC7810265/
Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease - PMC
Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology,...
https://adisinsight.springer.com/drugsafety/803873202?error=cookies_not_supported&code=afe5e0fe-5a40-48a0-8a7e-85e1066452e5
All lots of voxelotor withdrawn in all markets - AdisInsight
Pfizer has announced that it is voluntarily withdrawing all lots of voxelotor (OXBRYTA) for the treatment of sickle cell disease (SCD) in all markets where it
all lotswithdrawnmarketsadisinsight